Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 5/20 | 0.59 |
| ▸ | HTT | P42858 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | HPGD | P15428 | 4/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28051135 | 0.88 | HTT (0.52) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL28051137 | 0.88 | HTT (0.61) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL28252795 | 0.86 | HTT (0.50) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL28051139 | 0.85 | MEN1 (0.51) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL28051054 | 0.84 | MAPT (0.67) | MAPTMEN1KMT2ALMNASMN1; SMN2 | |
| SCHEMBL28051140 | 0.84 | MAPT (0.64) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL28059516 | 0.81 | KMT2A (0.53) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL28051136 | 0.81 | KMT2A (0.58) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL27651554 | 0.80 | MEN1 (0.53) | MAPTMEN1KMT2ALMNAHTT | |
| SCHEMBL27801439 | 0.80 | MAPT (0.69) | MAPTMEN1KMT2ALMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105287388-B | High dispersive carbazole sulfonamide derivative and preparation method thereof | 山西普德药业有限公司 | 2019-09-17 | — | — | CN | claimed |
| CN-105418487-B | Carbazole sulfonamide derivative eutectic and preparation method thereof | 山西普德药业有限公司 | 2018-11-02 | — | — | CN | claimed |
| CN-105418487-A | Carbazole sulfonamide derivative eutectic and preparation method thereof | SHANXI PUDE PHARMACEUTICS CO LTD | 2016-03-23 | — | — | CN | claimed |
| CN-105287388-A | High-dispersion carbazole sulfonamide derivatives and preparation method thereof | SHANXI PUDE PHARMACEUTICS CO LTD | 2016-02-03 | — | — | CN | claimed |
| US-20220380367-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | THE UNIVERSITY OF MONTANA | 2022-12-01 | — | — | US | disclosed |
| US-11420967-B2 | Modified carbazoles as therapeutic agents | UNIVERSITY OF WASHINGTON (US) | 2022-08-23 | — | — | US | disclosed |
| EP-3807262-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | University of Washington (US) | 2021-04-21 | — | — | EP | disclosed |
| US-20210094949-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | THE UNIVERSITY OF MONTANA | 2021-04-01 | — | — | US | disclosed |
| CN-105287388-B | High dispersive carbazole sulfonamide derivative and preparation method thereof | 山西普德药业有限公司 | 2019-09-17 | — | — | CN | disclosed |
| CN-105418487-B | Carbazole sulfonamide derivative eutectic and preparation method thereof | 山西普德药业有限公司 | 2018-11-02 | — | — | CN | disclosed |
| CN-105418487-A | Carbazole sulfonamide derivative eutectic and preparation method thereof | SHANXI PUDE PHARMACEUTICS CO LTD | 2016-03-23 | — | — | CN | disclosed |
| CN-105287388-A | High-dispersion carbazole sulfonamide derivatives and preparation method thereof | SHANXI PUDE PHARMACEUTICS CO LTD | 2016-02-03 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380367-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, TUBA1C | MAPT 23/4885MEN1 3161/4885KMT2A 2467/4885 |
| US-20210094949-A1 | MODIFIED CARBAZOLES AS THERAPEUTIC AGENTS | TUBB3, TUBB1, TUBA1C | MAPT 23/4885MEN1 3161/4885KMT2A 2467/4885 |
| US-11420967-B2 | Modified carbazoles as therapeutic agents | TUBB3, TUBB1, TUBA1C | MAPT 23/4885MEN1 3161/4885KMT2A 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.